# Zofia T Bilinska

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 63 papers | 3,047 citations | 20 h-index | 55 g-index |
| 67 ext. papers | 3,714 ext. citations | 4.4 avg, IF | 3.99 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 63 | Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. *European Heart Journal*, **2008**, 29, 270-6 | 9.5 | 1641 |
| 62 | Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *European Heart Journal*, **2010**, 31, 2715-26 | 9.5 | 324 |
| 61 | Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. *European Heart Journal*, **2008**, 29, 1350-8 | 9.5 | 148 |
| 60 | Does p.Q247X in TRIM63 cause human hypertrophic cardiomyopathy?. *Circulation Research*, **2014**, 114, e2-5 | 15.7 | 73 |
| 59 | In vivo and in vitro examination of the functional significances of novel lamin gene mutations in heart failure patients. *Journal of Medical Genetics*, **2005**, 42, 639-47 | 5.8 | 67 |
| 58 | Genetic and ultrastructural studies in dilated cardiomyopathy patients: a large deletion in the lamin A/C gene is associated with cardiomyocyte nuclear envelope disruption. *Basic Research in Cardiology*, **2010**, 105, 365-77 | 11.8 | 64 |
| 57 | The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. *European Heart Journal*, **2018**, 39, 1784-1793 | 9.5 | 60 |
| 56 | Determinants of prognosis in nonischemic dilated cardiomyopathy. *Journal of Cardiac Failure*, **1996**, 2, 77-85 | 3.3 | 56 |
| 55 | Dilated Cardiomyopathy Due to BLC2-Associated Athanogene 3 (BAG3) Mutations. *Journal of the American College of Cardiology*, **2018**, 72, 2471-2481 | 15.1 | 53 |
| 54 | The BAG3 gene variants in Polish patients with dilated cardiomyopathy: four novel mutations and a genotype-phenotype correlation. *Journal of Translational Medicine*, **2014**, 12, 192 | 8.5 | 48 |
| 53 | Titin Truncating Variants in Dilated Cardiomyopathy - Prevalence and Genotype-Phenotype Correlations. *PLoS ONE*, **2017**, 12, e0169007 | 3.7 | 46 |
| 52 | Lamin A/C mutations in dilated cardiomyopathy. *Cardiology Journal*, **2014**, 21, 331-42 | 1.4 | 38 |
| 51 | Next-generation sequencing for diagnosis of thoracic aortic aneurysms and dissections: diagnostic yield, novel mutations and genotype phenotype correlations. *Journal of Translational Medicine*, **2016**, 14, 115 | 8.5 | 36 |
| 50 | Autophagy in transition from hypertrophic cardiomyopathy to heart failure. *Journal of Electron Microscopy*, **2010**, 59, 181-3 | | 31 |
| 49 | A study in Polish patients with cardiomyopathy emphasizes pathogenicity of phospholamban (PLN) mutations at amino acid position 9 and low penetrance of heterozygous null PLN mutations. *BMC Medical Genetics*, **2015**, 16, 21 | 2.1 | 26 |
| 48 | Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the Gene. *Circulation: Heart Failure*, **2020**, 13, e006832 | 7.6 | 24 |
| 47 | Evidence for troponin C (TNNC1) as a gene for autosomal recessive restrictive cardiomyopathy with fatal outcome in infancy. *American Journal of Medical Genetics, Part A*, **2016**, 170, 3241-3248 | 2.5 | 23 |

| | | | |
|---|---|---|---|
| 46 | Specific contribution of lamin A and lamin C in the development of laminopathies. *Experimental Cell Research*, **2008**, 314, 2362-75 | 4.2 | 21 |
| 45 | Variants of the lamin A/C (LMNA) gene in non-valvular atrial fibrillation patients: a possible pathogenic role of the Thr528Met mutation. *Molecular Diagnosis and Therapy*, **2012**, 16, 99-107 | 4.5 | 20 |
| 44 | Coronary computed tomographic angiography for prediction of procedural and intermediate outcome of bypass grafting to left anterior descending artery occlusion with failed visualization on conventional angiography. *American Journal of Cardiology*, **2012**, 109, 1722-8 | 3 | 20 |
| 43 | Obliteration of cardiomyocyte nuclear architecture in a patient with LMNA gene mutation. *Journal of the Neurological Sciences*, **2008**, 271, 91-6 | 3.2 | 20 |
| 42 | Rapid and effective response of the R222Q SCN5A to quinidine treatment in a patient with Purkinje-related ventricular arrhythmia and familial dilated cardiomyopathy: a case report. *BMC Medical Genetics*, **2018**, 19, 94 | 2.1 | 18 |
| 41 | Homozygous truncating mutation in NRAP gene identified by whole exome sequencing in a patient with dilated cardiomyopathy. *Scientific Reports*, **2017**, 7, 3362 | 4.9 | 17 |
| 40 | Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23. *European Heart Journal*, **2021**, 42, 2000-2011 | 9.5 | 14 |
| 39 | Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm. *Pharmacogenetics and Genomics*, **2013**, 23, 611-8 | 1.9 | 12 |
| 38 | Variable clinical presentation of glycogen storage disease type IV: from severe hepatosplenomegaly to cardiac insufficiency. Some discrepancies in genetic and biochemical abnormalities. *Archives of Medical Science*, **2018**, 14, 237-247 | 2.9 | 12 |
| 37 | A new c.1621 C > G, p.R541G lamin A/C mutation in a family with DCM and regional wall motion abnormalities (akinesis/dyskinesis): genotype-phenotype correlation. *Journal of Human Genetics*, **2011**, 56, 83-6 | 4.3 | 10 |
| 36 | Usefulness of 1H MR spectroscopy in the evaluation of myocardial metabolism in patients with dilated idiopathic cardiomyopathy: pilot study. *Academic Radiology*, **2003**, 10, 1187-92 | 4.3 | 10 |
| 35 | LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies. *BMC Medical Genetics*, **2013**, 14, 55 | 2.1 | 8 |
| 34 | Dilated cardiomyopathy with profound segmental wall motion abnormalities and ventricular arrhythmia caused by the R541C mutation in the LMNA gene. *International Journal of Cardiology*, **2010**, 144, e51-3 | 3.2 | 8 |
| 33 | Quantification of mitral regurgitation in patients with hypertrophic cardiomyopathy using aortic and pulmonary flow data: impacts of left ventricular outflow tract obstruction and different left ventricular segmentation methods. *Journal of Cardiovascular Magnetic Resonance*, **2017**, 19, 105 | 6.9 | 7 |
| 32 | Platelet reactivity on aspirin, clopidogrel and abciximab in patients with acute coronary syndromes and reduced estimated glomerular filtration rate. *Thrombosis Research*, **2010**, 125, 67-71 | 8.2 | 7 |
| 31 | Restrictive cardiomyopathy due to novel desmin gene mutation. *Kardiologia Polska*, **2017**, 75, 723 | 0.9 | 7 |
| 30 | Dilated cardiomyopathy caused by LMNA mutations. Clinical and morphological studies. *Kardiologia Polska*, **2006**, 64, 812-9; discussion 820-1 | 0.9 | 7 |
| 29 | Cumulative incidence of coronary lesions with vulnerable characteristics in patients with stable angina pectoris: an intravascular ultrasound and angiographic study. *International Journal of Cardiology*, **2005**, 102, 201-6 | 3.2 | 6 |

| | | | |
|---|---|---|---|
| 28 | Organ-specific cardiac autoantibodies in dilated cardiomyopathy. Frequency and clinical correlates in Polish patients. *European Heart Journal*, **1995**, 16, 1907-11 | 9.5 | 6 |
| 27 | Sudden cardiac arrest in patients without overt heart disease: a limited value of next generation sequencing. *Polish Archives of Internal Medicine*, **2018**, 128, 721-730 | 1.9 | 6 |
| 26 | Analysis of Mutations in Sporadic Cardiomyopathies Emphasizes Their Clinical Relevance and Points to Novel Candidate Genes. *Journal of Clinical Medicine*, **2020**, 9, | 5.1 | 5 |
| 25 | Increased frequency of organ-specific cardiac antibodies in healthy relatives of patients with dilated cardiomyopathy: evidence for autoimmunity in Polish families. *Clinical Cardiology*, **1996**, 19, 794-8 | 3.3 | 5 |
| 24 | Can Circulating Cardiac Biomarkers Be Helpful in the Assessment of Mutation Carriers?. *Journal of Clinical Medicine*, **2020**, 9, | 5.1 | 4 |
| 23 | Impact of cardiac magnetic resonance on the diagnosis of hypertrophic cardiomyopathy - a 10-year experience with over 1000 patients. *European Radiology*, **2021**, 31, 1194-1205 | 8 | 4 |
| 22 | Unexpected eosinophilic myocarditis in a young woman with rapidly progressive dilated cardiomyopathy. *International Journal of Cardiology*, **2002**, 86, 295-7 | 3.2 | 3 |
| 21 | A different background of arrhythmia in siblings with a positive family history of sudden death at young age. *Annals of Noninvasive Electrocardiology*, **2020**, 25, e12707 | 1.5 | 3 |
| 20 | A combination of quinidine/mexiletine reduces arrhythmia in dilated cardiomyopathy in two patients with R814W SCN5A mutation. *ESC Heart Failure*, **2020**, 7, 4326 | 3.7 | 3 |
| 19 | ESC EORP Cardiomyopathy Registry: real-life practice of genetic counselling and testing in adult cardiomyopathy patients. *ESC Heart Failure*, **2020**, 7, 3013-3021 | 3.7 | 3 |
| 18 | Severe Course of Peripartum Cardiomyopathy and Subsequent Recovery in a Patient with a Novel TTN Gene-Truncating Mutation. *American Journal of Case Reports*, **2018**, 19, 820-824 | 1.3 | 3 |
| 17 | Baseline clinical characteristics and midterm prognosis of STE-ACS and NSTE-ACS patients with normal coronary arteries. *Annals of Noninvasive Electrocardiology*, **2009**, 14, 4-12 | 1.5 | 2 |
| 16 | Left ventricular enlargement is common in relatives of patients with dilated cardiomyopathy. *Journal of Cardiac Failure*, **1995**, 1, 347-53 | 3.3 | 2 |
| 15 | Novel truncating desmoplakin mutation as a potential cause of sudden cardiac death in a family. *Polish Archives of Internal Medicine*, **2016**, 126, 704-707 | 1.9 | 2 |
| 14 | Autosomal recessive transmission of familial nonsyndromic dilated cardiomyopathy due to compound desmoplakin gene mutations. *Polish Archives of Internal Medicine*, **2018**, 128, 785-787 | 1.9 | 2 |
| 13 | Sudden cardiac death risk in hypertrophic cardiomyopathy: comparison between echocardiography and magnetic resonance imaging. *Scientific Reports*, **2021**, 11, 7146 | 4.9 | 2 |
| 12 | A Recurrent Exertional Syncope and Sudden Cardiac Arrest in a Young Athlete with Known Pathogenic p.Arg420Gln Variant in the Gene. *Diagnostics*, **2020**, 10, | 3.8 | 1 |
| 11 | A fatal outcome of thoracic aortic aneurysm in a male patient with bicuspid aortic valve. *Postepy W Kardiologii Interwencyjnej*, **2013**, 9, 265-71 | 0.4 | 1 |

# List of Publications

| | | | |
|---|---|---|---|
| 10 | The protective effect of influenza vaccination on the clinical course of coronary disease in patients with acute coronary syndromes treated by primary PCI a report from FLUCAD study. *Postepy W Kardiologii Interwencyjnej*, **2010**, 1, 6-11 | 0.4 | 1 |
| 9 | A Novel Truncating Variant in a Family with Episodic Myocardial Injury in the Course of Arrhythmogenic Cardiomyopathy-A Possible Role of a Low Penetrance Variant. *Diagnostics*, **2020**, 10, | 3.8 | 1 |
| 8 | Familial dilated cardiomyopathy: evidence for clinical and immunogenetic heterogeneity. *Medical Science Monitor*, **2003**, 9, CR167-74 | 3.2 | 1 |
| 7 | Good performance of the criteria of American College of Medical Genetics and Genomics/Association for Molecular Pathology in prediction of pathogenicity of genetic variants causing thoracic aortic aneurysms and dissections.. *Journal of Translational Medicine*, **2022**, 20, 42 | 8.5 | 0 |
| 6 | Tripeptidyl Peptidase 1 (TPP1) Deficiency in a 36-Year-Old Patient with Cerebellar-Extrapyramidal Syndrome and Dilated Cardiomyopathy.. *Life*, **2021**, 12, | 3 | 0 |
| 5 | Clinical Applications for Next Generation Sequencing in Cardiology **2016**, 189-215 | | |
| 4 | A new missense mutation, p.Arg719Leu, of the beta-myosin heavy chain gene in a patient with familial hypertrophic cardiomyopathy. *Minerva Cardiology and Angiology*, **2017**, 65, 96-102 | 2.4 | |
| 3 | Therapeutic challenges and management of heart failure during pregnancy (part 2). *Medical Science Monitor*, **2012**, 18, CQ9-13 | 3.2 | |
| 2 | Therapeutic challenges and management of heart failure during pregnancy (part I). *Medical Science Monitor*, **2012**, 18, CQ5-7 | 3.2 | |
| 1 | Autoimmune Myocarditis: Treatment with Anti-T-Cell Antibodies256-262 | | |